Zealand commits $30 million to Generate for AI-designed obesity drugs

Zealand Pharma is committing $30 million upfront to AI-designed drug research—not buying a proven obesity treatment. Its October 13, 2026 agreement with Generate Biomedicines carries nearly $1.2 billion in potential milestones. The companies plan to develop protein medicines for obesity and other metabolic diseases, with research and candidate selection preceding Zealand’s clinical-development work.

The collaboration and license agreement covers two initial programs, with an option to add a third. It pairs Zealand’s metabolic-disease expertise with Generate’s protein-design platform. For Zealand, the agreement adds another way to develop medicines beyond its existing small-molecule and peptide capabilities. For Generate, it extends the platform into obesity and other metabolic diseases.

The billion-dollar figure is conditional

The financial terms separate the payment at signing from payments linked to later progress. Generate will receive the upfront money and could receive up to $35 million in early preclinical milestones. Those milestones concern work before clinical development, the stage Zealand will lead under the agreement.

Nearly $1.2 billion is the potential total milestone amount for the two initial programs, not a payment being made now. It includes possible development, regulatory and commercial milestones.

Generate is also eligible for tiered royalties on future worldwide net sales of products commercialized through the collaboration.

Designing proteins, then testing the designs

The proposed medicines are multispecific protein therapeutics, intended to address multiple biological targets. The companies want to create candidates with tailored biological functions, rather than simply apply AI to administrative work around drug development. Generate’s assignment is to engineer the proteins themselves using its proprietary platform.

Generate says the platform combines generative AI with high-throughput experimental validation: testing designs at scale and using experimental data to refine them toward the desired biological function.

The companies frame that combination as a way to accelerate design and development. Zealand chief scientific officer Utpal Singh described the agreement as adding proteins to the company’s existing tools and opening new approaches to medicines acting across several targets.

Together, our teams will first define what a great medicine for patients looks like for each of the two initial programs, and then leverage The Generate Platform to design multispecific candidates that meet or exceed that profile.

Mike Nally, chief executive officer of Generate Biomedicines

Candidate selection is the handoff

Generate will lead research through lead-candidate selection—the choice of a candidate to advance. Zealand will then take responsibility for subsequent clinical development, regulatory submissions and worldwide commercialization.